Cyclopentanohydrophenanthrene Ring System Containing Patents (Class 552/502)
  • Patent number: 6500669
    Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: December 31, 2002
    Assignee: Massachusetts Institute of Technology
    Inventors: John M. Essigmann, Robert G. Croy, Kevin J. Yarema, Marshall Morningstar
  • Patent number: 6468981
    Abstract: A water soluble delivery system for nucleic acids to cells having androgen receptors, preferably prostate cells, is provided comprising a steroid moiety capable of binding to said receptors, said steroid moiety being covalently linked to a polycationic material. This molecule may be complexed with therapeutic or diagnostic nucleic acids. Methods of diagnosis and therapy using these compositions are also provided, including gene therapy treatments for prostate cancer.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: October 22, 2002
    Assignee: Emory University
    Inventors: John Anthony Petros, Dennis C. Liotta
  • Patent number: 6407270
    Abstract: The present invention provides a method for preparing an ester of betulin at the 3-position, e.g., betulin-3-acetate, including the selective alcoholysis of a betulin-3,28-diester, e.g., betulin-3,28-diacetate; a method for preparing betulin-3-acetate including (1) acetylating betulin to provide betulin-3,28-diacetate and (2) the alcoholysis of betulin-3,28-diacetate to provide betulin-3-acetate; a method for preparing betulinic acid from betulin-3-acetate including (1) acetylating betulin to provide betulin-3,28-diacetate, (2) the alcoholysis of betulin-3,28-diacetate to provide betulin-3-acetate, (3) oxidizing betulin-3-acetate to provide betulinic aldehyde-3-acetate, (4) oxidizing betulinic aldehyde-3-acetate to provide betulinic acid-3-acetate, and (5) deprotecting betulinic acid-3-acetate to provide betulinic acid.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: June 18, 2002
    Assignee: Regents of the University of Minnesota
    Inventors: Pavel A. Krasutsky, Robert M. Carlson, Vitaliy V. Nesterenko
  • Publication number: 20020045772
    Abstract: A steroid intermediate has the formula (II): 1
    Type: Application
    Filed: October 17, 2001
    Publication date: April 18, 2002
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Hiroyoshi Watanabe
  • Publication number: 20020016455
    Abstract: Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I 1
    Type: Application
    Filed: April 3, 2001
    Publication date: February 7, 2002
    Inventors: John S. Ng, Ping T. Wang, Julio A. Baez, Chin Liu, Dennis K. Anderson, Jon P. Lawson, Bernhard Erb, Joseph Wieczorek, Gennaro Mucciariello, Fortunato Vanzanella, Sastry A. Kunda, Leo J. Letendre, Mark J. Pozzo, Yuen-Lung L. Sing, Edward E. Yonan
  • Patent number: 6322784
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: November 27, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen C. Beck
  • Patent number: 6313327
    Abstract: This invention relates to novel carboxylic acid derivatives represented by the following formula I and their synthesis: wherein, R1 is an hydrogen atom, an alkyl group or an alkoxy group of 1 to 20 carbon atoms in a linear, branched or cyclic form; R2 is a carboxy group of 1 to 40 carbon atoms in a linear, branched or cyclic form which is unsubstituted, or substituted into a hydroxy group, an ester group and an ether group. The novel carboxylic acid derivatives are more easily decomposed by acid than t-butyl ester compounds but are not dissolved in basic aqueous solution. According to this invention, carboxylic acid is under condensation with halogen compounds designed to prepare a larger monomolecular compound compared to the conventional method. Further, the condensed site is easily decomposed by acid but is extremely insoluble by basic aqueous solution.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: November 6, 2001
    Assignee: Korea Kumho Petrochemical Co., Ltd.
    Inventors: Dong Seoul Seo, Joo Hyeon Park, Jae Young Kim, Seong Ju Kim
  • Patent number: 6303589
    Abstract: The present invention relates to fungicidally effective compositions containing at least one pentacyclic triterpene compound.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: October 16, 2001
    Assignee: Micro Flo Company
    Inventors: Jan Glinski, Keith L. Branly
  • Patent number: 6232481
    Abstract: The present invention provides a method for preparing betulin-3-acetate including alcoholyzing betulin 3,28-dibenzoate; a process for preparing betulin-3-acetate including: (1) acylating betulin to provide betulin 3,28-dibenzoate and (2) alcoholyzing betulin 3,28-dibenzoate to provide betulin-3-acetate; and a process for preparing betulinic acid including: (1) acylating betulin to provide betulin 3,28-dibenzoate; (2) alcoholyzing betulin 3,28-dibenzoate to provide betulin-3-acetate; (3) oxidizing betulin-3-acetate to provide betulinic aldehyde-3-acetate; (4) oxidizing betulinic aldehyde-3-acetate to provide betulinic acid-3-acetate; and (5) deprotecting betulinic acid-3-acetate to provide betulinic acid.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: May 15, 2001
    Assignees: Regents of the University of Minnesota, Naturtek, LLC
    Inventors: Pavel A. Krasutsky, Robert M. Carlson, Vitaliy V. Nesterenko
  • Patent number: 6197332
    Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: March 6, 2001
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
  • Patent number: 6177417
    Abstract: The present invention relates to a cholanic acid ring based 4-(trifluoroacetyl)phenyl derivatives of the following formula 1, process for preparation and use thereof. The cholanic acid ring based 4-(trifluoroacetyl)phenyl derivatives of the present invention may be used as a host material in the host-guest chemistry, in detail as a material for ion sensors, optical sensors, gas sensors, biosensors, chromatographies, photostimulated ion-binding resins, ion exchange resins and organic reactions. (In the above formula 1, R, R1, R2, R3 and n are defined in the specifications).
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: January 23, 2001
    Inventors: Junho Chu, Hyung Jung Pyun, In Jun Yoon, Jae Ho Shin, Hakhyun Nam, Geun Sig Cha
  • Patent number: 6174665
    Abstract: The present invention provides methods for monitoring the effectiveness of hormone replacement therapy in a perimenopausal, early menopausal, or late menopausal woman, comprising testing for hormonal levels in a body fluid of the woman at intervals depending on the stage of menopause, and adjusting levels of replacement hormone administered to the woman based on the test results.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: January 16, 2001
    Assignee: Biex, Inc.
    Inventor: Vivian Dullien
  • Patent number: 6175035
    Abstract: A method of producing betulinic acid from the bark of plane trees by fractional extraction with a solvent of medium polarity and subsequent recrystallization out of methanol.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: January 16, 2001
    Inventors: Birgit Draeger, Tino Galgon, Reinhard Neubert, Wolfgang Wohlrab
  • Patent number: 6127140
    Abstract: A method for determining concentration of an analyte in a biological sample comprising the steps of:(a) combining the biological sample, at least one oxidizing enzyme for the analyte of interest, nicotinamide adenine dinucleotide (hereinafter NAD.sup.+), and a chemiluminescent label to form a reaction mixture;(b) allowing the analyte to undergo an oxidation-reduction reaction and NAD.sup.+ to be converted to the reduced form of nicotinamide adenine dinucleotide (hereinafter NADH) and further allowing the chemiluminescent label to react with NADH; and(c) determining the concentration of the analyte of interest in the biological sample by correlating the quantity of light emitted with the concentration of NADH.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: October 3, 2000
    Assignee: Abbott Laboratories
    Inventors: Momcilo S. Vidakovic, David C. Leahy, Donna M. Massie
  • Patent number: 6087090
    Abstract: Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or biochemical parameters) for a test group before and after treatment with the drug or regimen. These values are used formulate a specific predictive method for the particular drug or treatment regimen. The predictive measurement is then used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen. The predictive methods may also be used to determine the equivalence of different dosages of a drug.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: July 11, 2000
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventor: Desmond Mascarenhas
  • Patent number: 6046186
    Abstract: Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have the structural formula (I) wherein r1 is an optional double bond, R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen and lower alky, or together form a cyclic substituent (II) ##STR1## wherein Q is NH, O or CH.sub.2, and the other various substituents are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat estrogen-dependent disorders are provided as well.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: April 4, 2000
    Assignee: SRI International
    Inventors: Masato Tanabe, Richard H. Peters, Wan-Ru Chao, Kazuhiko Shigeno
  • Patent number: 6043026
    Abstract: The combination of an estrogen receptor modulator and a growth hormone secretagogue is useful in the treatment or prevention of diseases involving bone resorption, especially osteoporosis.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: March 28, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Arthur A. Patchett, Gideon A. Rodan
  • Patent number: 6025332
    Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: February 15, 2000
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventor: Desmond Mascarenhas
  • Patent number: 6017906
    Abstract: The present invention relates to methods of preventing or treating an infection or disease caused by an infectious agent. The present invention also relates to the augmentation of the efficacy of existing anti-infective agents by the co-administration of the compounds described herein.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: January 25, 2000
    Assignee: Intercardia, Inc.
    Inventors: Clifford S. Mintz, Natan A. Kogan, Ramesh Kakarla, Helena R. Axelrod, Michael J. Sofia
  • Patent number: 5994568
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5981744
    Abstract: Multiple reaction schemes, process steps and intermediates are provided for the synthesis of epoxymexrenone, useful as a diuretic, and other 9,11-epoxy-steroids.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: November 9, 1999
    Assignee: G. D. Searle and Co.
    Inventors: John S. Ng, Ping T. Wang, Julio A. Baez, Chin Liu, Dennis K. Anderson, Jon P. Lawson, Bernhard Erb, Joseph Wieczorek, Sastry A. Kunda, Leo J. Letendre, Mark J. Pozzo, Yuen-Lung L. Sing, Edward E. Yonan
  • Patent number: 5882941
    Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.
    Type: Grant
    Filed: May 4, 1994
    Date of Patent: March 16, 1999
    Assignee: Massachusette Institute of Technology
    Inventors: John M. Essigmann, Robert G. Croy, Zhenghuan Chen
  • Patent number: 5869081
    Abstract: The present invention relates to a method of administering progesterone to a normogonadal or a functionally agonadal human female undergoing an assisted reproduction technique. The invention further provides a method of hormone replacement for a human female. In a preferred embodiment of the present invention, progesterone is provided by intravaginal administration of a progesterone-containing polysiloxane ring.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: February 9, 1999
    Assignee: The Population Council
    Inventors: Theodore Jackanicz, Horacio B. Croxatto Avoni, Leopoldo Glasser Drexler, Fernando Zegers-Hochschild
  • Patent number: 5852005
    Abstract: The present invention relates to 17 .alpha.-dammara compounds having immunosuppressant and antiinflammatory activity and which are useful as pharmaceuticals, particularly for use as immunosuppressant and antiinflammatory agents. Specific 17 .alpha.-dammara compounds are included per se, for example the compound of formula IC, i.e. 17 .alpha.-23-(E)-dammara-20, 23-dien-3.beta., 25-diol, which may be obtained from the flour of the shoots of the Palmyrah palm, Borassus flabellifer L. In addition, processes for the synthesis of this and other dammara compounds and intermediates thereof are described.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: December 22, 1998
    Assignee: Novartis AG
    Inventors: Peter Hiestand, Reto Naef, Hans-Ulrich Naegeli, Lukas Oberer, Laszlo Revesz, Hans-Jorg Roth
  • Patent number: 5849724
    Abstract: A Chrysosporium strain No. CBS 123.95, mutants and derivatives thereof, and a method for preparing non-peptide compounds using said strain, are disclosed. Novel compounds of general formula (I), pharmaceutical compositions containing same, and the use of said compounds in anticancer treatments, are also disclosed.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: December 15, 1998
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jean Leboul, Didier Van der Pyl, Jean-Jacques Debernard
  • Patent number: 5843670
    Abstract: As a novel digoxigenin derivative which makes the labeling procedure simple, can be used to label a naturally-occurring nucleic acid, and enables highly sensitive assay, carbodiimide group-containing digoxigenin derivative represented by the following formula is used as the label in a nucleic acid detection method or immunoassay.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: December 1, 1998
    Assignee: Nisshinbo Industries, Inc.
    Inventors: Osamu Suzuki, Gen Masuda, Namiko Shiohata, Kazuko Matsumoto
  • Patent number: 5824467
    Abstract: Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or biochemical parameters) for a test group before and after treatment with the drug or regimen. These values are used formulate a specific predictive method for the particular drug or treatment regimen. The predictive measurement is then used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: October 20, 1998
    Assignee: Celtrix Pharmaceuticals
    Inventor: Desmond Mascarenhas
  • Patent number: 5804575
    Abstract: Improved methods of manufacturing betulinic acid from betulin are disclosed. The methods provide the .beta.-isomer of betulinic acid in high purity and high yield.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: September 8, 1998
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: John M. Pezzuto, Darrick S. H. L. Kim
  • Patent number: 5760255
    Abstract: The invention is drawn to a process for the conversion of primary and secondary alcohols into the corresponding fluorine compounds in the presence of an organic solvent, 2-3 equivalents of a strong base and perfluoroalkylsulphonyl fluorides, such as perfluorobutanesulphonyl fluoride or higher homologues.
    Type: Grant
    Filed: June 25, 1996
    Date of Patent: June 2, 1998
    Assignee: Bayer AG
    Inventors: Helmut Vorbruggen, Barbel Bennua-Skalmowski
  • Patent number: 5750679
    Abstract: A process for obtaining pharmacologically active compounds from complex mixtures of substancesFree organic acids, hydroxy acids, fatty alcohols, sugars and hydroxy-substituted steroids are obtained from complex mixtures of substances by mixing the material to be extracted with a polar solvent, drying the resulting mixture, subsequently silylating, esterifying or acylating, and extracting the resulting material with a supercritical fluid under a pressure of more than 200 bar.
    Type: Grant
    Filed: August 25, 1994
    Date of Patent: May 12, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Peter Haas, Heinz Engelhardt, Stefan Mullner
  • Patent number: 5744453
    Abstract: The present invention relates to methods of preventing or treating an infection or disease caused by an infectious agent. The present invention also relates to the augmentation of the efficacy of existing anti-infective agents by the co-administration of the compounds described herein.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: April 28, 1998
    Inventors: Clifford S. Mintz, Natan A. Kogan, Ramesh Kakarla, Helena R. Axelrod, Michael J. Sofia
  • Patent number: 5739302
    Abstract: There are described novel glycosides of catechol estrogen, a method of preparing the same, and a medicament comprising one of the glycosides as an active ingredient. The glycosides are shown by the formula of ##STR1## wherein X is carbonyl group or ##STR2## R.sub.10 is hydroxyl group or glycosyloxy group, and R.sub.2 is a hydrogen atom or ethynyl group; R.sub.11 is a hydrogen atom, hydroxyl group, or glycosyloxy group; R.sub.12 is hydroxyl group or glycosyloxy group; and R.sub.13 is hydroxyl group or glycosyloxy group, in which glycosyloxy group is selected from the group consisting of glycosyloxy, galactosyloxy, mannosyloxy, arabinosyloxy, ribosyloxy, xylosyloxy, fructosyloxy, rhamnosyloxy, fucosyloxy, maltosyloxy, cellobiosyloxy, lactosyloxy, sucrosyloxy, maltotriosyloxy, maltotetraosyloxy, maltopentaosyloxy, maltohexaosyloxy, maltoheptaosyloxy, and sialosyloxy, and in this case, at least one of R.sub.10, R.sub.11, R.sub.12, and R.sub.13 is glycosyloxy group as defined above.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: April 14, 1998
    Assignee: Institute of Applied Biochemistry
    Inventors: Takehiko Suzuki, Sadaaki Komura, Naoko Ishida, Nobuko Ohishi, Kunio Yagi
  • Patent number: 5739125
    Abstract: The invention relates to 11.beta.-aryl-gona-4,9-dienes of formula I ##STR1## wherein the variables are defined in the specification. The compounds are progesterone synthesis inhibitors and are suitable for inducing labor or an abortion, and for treating endometriosis, dysmenorrhea, and endocrine hormone-dependent tumors.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: April 14, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Helmut Kasch, Gudrun Bertram, Kurt Ponsold, Gerd Schubert, Heidemarie Rohrig, Anatoli Kurischko, Bernd Menzenbach
  • Patent number: 5723455
    Abstract: Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat androgen-related clinical conditions are provided, as are methods and compositions for using the compounds as contraceptive agents.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: March 3, 1998
    Assignee: SRI International
    Inventors: Masato Tanabe, Wan-Ru Chao, Wesley K. M. Chong, David F. Crowe
  • Patent number: 5641765
    Abstract: Invented are 17.alpha. and 17.beta.-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-.alpha.-reductase. Also invented are intermediates and processes used in preparing these compounds.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: June 24, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Dennis Alan Holt, Mark Alan Levy
  • Patent number: 5633392
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 27, 1997
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5612317
    Abstract: The present invention relates to methods for the treatment or prevention of osteoporosis and the alleviation of the symptoms of menopause by the administration of an estrogen glycoside or estrogen orthoester glycoside.
    Type: Grant
    Filed: August 4, 1994
    Date of Patent: March 18, 1997
    Inventor: Michael F. Holick
  • Patent number: 5585468
    Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: December 17, 1996
    Assignee: Cytogen Corporation
    Inventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
  • Patent number: 5561124
    Abstract: The invention relates to substituted 17.alpha.-acyl steroidal 5.alpha.-reductase inhibiting compounds. The invention also relates to pharmaceutical compositions containing these compounds and their use for reducing prostate size and treating prostate adenocarcinoma. Further, the invention describes a process for making these compounds by heating the corresponding substituted 17.beta.-acyl steroid in a solvent, such as ethylene glycol or dimethyl sulfoxide (DMSO), in a base, such as sodium or potassium hydroxide.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 1, 1996
    Inventor: Robert L. Webb
  • Patent number: 5519008
    Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: May 21, 1996
    Assignee: Glycomed Incorporated
    Inventors: Narasinga Rao, Mark B. Anderson, John J. Naleway, John H. Musser
  • Patent number: 5424457
    Abstract: A process is provided which allows the isolation of sterols and a tocopherol concentrate in high yields from a deodorizer distillate (DOD) mixture obtained from the processing of, for example, soybean oils. Treatment of DOD with methanol at preferably 200.degree.-220.degree. C. in the presence of a monoalkyl- or dialkyl-tin compound results in the conversion of fatty acids and fatty acid esters into fatty acid methyl esters (FAME) and the liberation of free sterols and glycerin without appreciable degradation of tocopherols or sterols. The process can also be carried out in two steps where glycerin is used in the initial step and the fatty acids are converted into glycerides allowing the water of reaction to be removed as it is formed. The FAME produced by both methods are removed by a stripping operation to give a concentrate that allows the isolation of sterols in high yield and high purity and the isolation of a tocopherol concentrate by molecular distillation.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: June 13, 1995
    Assignee: Eastman Chemical Company
    Inventors: Charles E. Sumner, Jr., Scott D. Barnicki, Martin D. Dolfi
  • Patent number: 5422393
    Abstract: A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: June 6, 1995
    Assignee: Naturon Pharmaceutical Corporation
    Inventors: Neal S. Bricker, William J. Wechter
  • Patent number: 5413996
    Abstract: The invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein [D] is the residue of a drug having a reactive functional group, said functional group being attached, directly or through a bridging group, via an oxygen-phosphorus bond to the phosphorus atom of the ##STR2## moiety; R.sub.1 is C.sub.1 -C.sub.8 alkyl, C.sub.6 -C.sub.10 aryl or C.sub.7 -C.sub.12 aralkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.6 -C.sub.10 aryl, C.sub.4 -C.sub.9 heteroaryl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloheteroalkyl or C.sub.7 -C.sub.12 aralkyl; and R.sub.3 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl having one or two double bonds; (C.sub.3 -C.sub.7 cycloalkyl)--C.sub.r H.sub.2r -- wherein r is zero, one, two or three, the cycloalkyl portion being unsubstituted or bearing 1 or 2 C.sub.1 -C.sub.4 alkyl substituents on the ring portion; (C.sub.6 -C.sub.10 aryloxy)C.sub.1 -C.sub.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: May 9, 1995
    Assignee: University of Florida
    Inventor: Nicholas S. Bodor
  • Patent number: 5405944
    Abstract: There are described novel glycosides of catechol estrogen, a method of preparing the same, and a medicament comprising one of the glycosides as an active ingredient. The glycosides are shown by the formula of ##STR1## wherein X is carbonyl group or ##STR2## R.sub.10 is hydroxyl group or glycosyloxy group, and R.sub.2 is a hydrogen atom or ethynyl group; R.sub.11 is a hydrogen atom, hydroxyl group, or glycosyloxy group; R.sub.12 is hydroxyl group or glycosyloxy group; and R.sub.13 is hydroxyl group or glycosyloxy group,in which glycosyloxy group is selected from the group consisting of glucosyloxy, galactosyloxy, mannosyloxy, arabinosyloxy, ribosyloxy, xylosyloxy, fructosyloxy, rhamnosyloxy, fucosyloxy, maltosyloxy, cellobiosyloxy, lactosyloxy, sucrosyloxy, maltotriosyloxy, maltotetraosyloxy, maltopentaosyloxy, maltohexaosyloxy, maltoheptaosyloxy, and sialosyloxy, and in this case, at least one of R.sub.10, R.sub.11, R.sub.12, and R.sub.13 is glycosyloxy group as defined above.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: April 11, 1995
    Assignee: Institute of Applied Biochemistry
    Inventors: Takehiko Suzuki, Sadaaki Komura, Naoko Ishida, Nobuko Ohishi, Kunio Yagi
  • Patent number: 5326856
    Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.
    Type: Grant
    Filed: April 9, 1992
    Date of Patent: July 5, 1994
    Assignee: Cytogen Corporation
    Inventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
  • Patent number: 5292906
    Abstract: Novel tricyclic steroid analogs are disclosed which are 1H-benz[e]indene dodecahydro compounds that are useful for enhancing GABA-induced chloride currents at the GABA receptor/chloride ionophore complex and can be represented by the following structural formulas: ##STR1## wherein R.sub.1 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl;R.sub.2 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl, in which R.sub.1 and R.sub.2 can be the same or different;R.sub.3 =H or CH.sub.3 ;R.sub.4 =H or CH.sub.3, in which R.sub.3 and R.sub.4 can be the same or different;R.sub.5 =H;R.sub.6 =H;R.sub.5,R.sub.6 =.dbd.O(carbonyl);R.sub.7 =H;R.sub.8 =a hydrogen bond accepting group.R.sub.7,R.sub.8 =.dbd.O(carbonyl); andR'=an ester group.
    Type: Grant
    Filed: January 14, 1993
    Date of Patent: March 8, 1994
    Assignee: Washington University
    Inventors: Douglas F. Covey, Yuefei Hu, Charles F. Zorumski
  • Patent number: 5208263
    Abstract: Disclosed are novel classes of anti-androgen including dihydrophenanthrene derivatives, their method of synthesis and their use in treating disorders associated with excessive androgenic activities.
    Type: Grant
    Filed: September 27, 1989
    Date of Patent: May 4, 1993
    Assignee: Arch Development Corporation
    Inventors: Shutsung Liao, John Pataki, Ronald G. Harvey
  • Patent number: 5182381
    Abstract: Novel 3-keto-19-nor-.DELTA..sup.4,9 -steroids of the formula ##STR1## and their non-toxic, pharmaceutically acceptable acid addition salts possessing a remarkable antiglucocorticoidal activity.
    Type: Grant
    Filed: September 10, 1991
    Date of Patent: January 26, 1993
    Assignee: Roussel Ulcaf
    Inventors: Daniel Philibert, Jean G. Teutsch, Germain Costerousse, Roger Deraedt
  • Patent number: 5177064
    Abstract: The invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein [D] is the residue of a drug having a reactive functional group, said functional group being attached, directly or through a bridging group, via an oxygen-phosphorus bond to the phosphorus atom of the ##STR2## moiety; R.sub.1 is C.sub.1 -C.sub.8 alkyl, C.sub.6 -C.sub.10 aryl or C.sub.7 -C.sub.12 aralkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.6 -C.sub.10 aryl, C.sub.4 -C.sub.9 heteroaryl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloheteroalkyl or C.sub.7 -C.sub.12 aralkyl; and R.sub.3 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl having one or two double bonds; (C.sub.3 -C.sub.7 cycloalkyl)--C.sub.r H.sub.2r --wherein r is zero, one, two or three, the cycloalkyl portion being unsubstituted or bearing 1 or 2 C.sub.1 -C.sub.4 alkyl substituents on the ring portion; (C.sub.6 -C.sub.10 aryloxy)C.sub.1 -C.sub.
    Type: Grant
    Filed: July 13, 1990
    Date of Patent: January 5, 1993
    Assignee: University of Florida
    Inventor: Nicholas S. Bodor
  • Patent number: 5030626
    Abstract: There are disclosed herein novel derivatives of 26,26,26,27,27,27-hexafluorovitamin D.sub.3 providing excellent pharmacological effects, and a process for the preparation thereof. These novel compounds are represented by the general formula ##STR1## wherein R.sub.1 and R.sub.2 each denotes a hydrogen atom or a protecting group for the hydroxyl group; R.sub.3 and R.sub.4 each denotes a hydrogen atom, a hydroxyl group or a protected hydroxyl group and R.sub.4 ' and R.sub.5 ' each denotes a hydrogen atom, or alternatively R.sub.3 and R.sub.3 ' together or R.sub.4 and R.sub.4 ' together denote an oxo group; provided that R.sub.3, R.sub.3 ', R.sub.4 and R.sub.4 ' cannot denote hydrogen atoms simultaneously. The process for the preparation comprises subjecting a previtamin D.sub.3 derivative represented by the formula ##STR2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.3 ', R.sub.4 and R.sub.4 ' are as defined above, to thermal isomerization to give a vitamin D.sub.
    Type: Grant
    Filed: April 24, 1990
    Date of Patent: July 9, 1991
    Assignees: Sumitomo Pharmaceuticals Company, Limited, Taisho Pharmaceutical Co., Ltd.
    Inventors: Noritaka Hamma, Yoshikazu Saito, Toshio Nishizawa, Takashi Katsumata, Itsuro Sugata